Shots:
- The CHMP has recommended Shingrix in a PFS (Recombinant Zoster Vaccine or RZV), simplifying administration by eliminating vial reconstitution for the prevention of shingles (herpes zoster). EU marketing authorization is expected in December 2025
- The opinion was based on data showing that the PFS matches the existing vaccine
- Shingrix combines glycoprotein E antigen with AS01B adjuvant to boost immune response and help protect adults 50+ from shingles despite age-related immunity decline. Shingrix has been EU-approved since 2018 for adults 50+ and since 2020 for adults 18+ at higher risk, designed to boost immune response against varicella-zoster virus
Ref: GSK | Image: GSK | Press Release
Related News:- China’s NMPA Approves GSK’s Shingrix to Protect Individuals Against Shingles
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
